Perioperative study of IBI363 for MHC-II-negative advanced stomach cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new treatment called IBI363 given before and after surgery for people with a certain type of advanced stomach cancer that lacks the MHC-II marker. The goal is to see if it helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or gastroesophageal junction cancer that is advanced but has not spread to other organs (stages cT3-4aN+M0).
- Your tumor cells do not have the MHC-II marker (less than 5% of cells show weak staining).
- You have not had any prior cancer treatment like chemotherapy, radiation, or immunotherapy for this current disease.
- You are scheduled to have surgery after receiving the study treatment.
- You are between 18 and 75 years old and able to swallow pills.
- Your overall health is good (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IBI363 in patients with advanced gastric or gastroesophageal junction cancer who have not yet received any treatment. The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
This trial tests a new drug called IBI363 for people with advanced cancer that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow cancer growth.
This trial tests a new combination of IBI343, sintilimab, and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't been treated yet. It's for those whose tumors are CLDN18.2-positive and not HER2-positive.
This trial tests a new drug called IBI343 combined with other treatments for people with advanced solid tumors that are CLDN18.2-positive. It aims to see if the combination can help shrink or control the cancer.
This trial tests whether adding a drug called tislelizumab (an immunotherapy) to standard chemotherapy before and after surgery is better than chemotherapy alone for people with a specific type of stomach or GEJ cancer that has a high level of a marker called MHC class II. The goal is to see if it helps shrink the tumor and improves the chance of successful surgery.
This study tests a new combination therapy (IBI363 with other drugs) for advanced colorectal cancer that is pMMR/MSI-L/MSS. It aims to understand how the immune system around the tumor changes during treatment.
Hear when a new IBI363 + Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.